Paper
0
Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
Authors
Journal
Published
Mar 1, 2024
Show more
Save
Tip0
TipSave
Abstract
Antibody-drug conjugates have transformed treatment for urothelial cancer (UC). Enfortumab vedotin is the new standard of care in the first-line setting for advanced UC. A personalised approach targeting HER2 in UC is currently being explored.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.